• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective.群体药代动力学-药效学分析质量控制指南:行业视角。
AAPS J. 2012 Dec;14(4):749-58. doi: 10.1208/s12248-012-9387-9. Epub 2012 Jul 24.
2
Reporting guidelines for population pharmacokinetic analyses.群体药代动力学分析报告指南。
J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):301-14. doi: 10.1007/s10928-015-9417-1. Epub 2015 Apr 30.
3
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements.药理学功能磁共振成像研究中良好成像实践的程序框架 #1:流程和要求。
Drug Discov Today. 2011 Jul;16(13-14):583-93. doi: 10.1016/j.drudis.2011.05.006. Epub 2011 May 24.
4
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.制药行业的临床前药代动力学/药效学建模与模拟:IQ联盟对当前现状的调查
AAPS J. 2015 Mar;17(2):462-73. doi: 10.1208/s12248-014-9716-2. Epub 2015 Jan 29.
5
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices.一种适用于药物开发的药理学 fMRI 研究中良好成像实践的程序框架#2:方案优化和最佳实践。
Drug Discov Today. 2011 Aug;16(15-16):671-82. doi: 10.1016/j.drudis.2011.03.011. Epub 2011 Apr 6.
6
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
7
The use of population pharmacokinetics in drug development.群体药代动力学在药物研发中的应用。
Clin Pharmacokinet. 1996 Feb;30(2):81-93. doi: 10.2165/00003088-199630020-00001.
8
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.医药行业的转化药代动力学-药效学分析:来自 IQ 联盟 PK-PD 讨论小组的观点。
Drug Discov Today. 2017 Oct;22(10):1447-1459. doi: 10.1016/j.drudis.2017.04.015. Epub 2017 May 2.
9
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.群体药代动力学和药代动力学/药效学分析的先验信息:概述及 NONMEM PRIOR 子程序重点指导
J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):431-446. doi: 10.1007/s10928-020-09695-z. Epub 2020 Jun 13.
10
Quality control and assurance from the development to the production of biopharmaceuticals.
Trends Biotechnol. 1999 Jul;17(7):266-70. doi: 10.1016/s0167-7799(99)01314-1.

引用本文的文献

1
The Dietary Biomarkers Development Consortium: An Initiative for Discovery and Validation of Dietary Biomarkers for Precision Nutrition.膳食生物标志物开发联盟:一项用于发现和验证精准营养膳食生物标志物的倡议。
Curr Dev Nutr. 2025 Apr 5;9(5):107435. doi: 10.1016/j.cdnut.2025.107435. eCollection 2025 May.
2
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.在临床实践中,将群体药代动力学建模与精准给药相结合的推荐方法。
Br J Clin Pharmacol. 2025 Apr;91(4):1064-1079. doi: 10.1111/bcp.16335. Epub 2024 Nov 21.
3
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.TLD-1(一种新型脂质体阿霉素)在 I 期临床试验中的群体药代动力学。
Cancer Chemother Pharmacol. 2024 Sep;94(3):349-360. doi: 10.1007/s00280-024-04679-z. Epub 2024 Jun 15.
4
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.依特司他的群体药代动力学:一种首创的寡核苷酸端粒酶抑制剂。
CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1264-1277. doi: 10.1002/psp4.13160. Epub 2024 May 21.
5
Improving pharmacometrics analysis efficiency using DataCheQC: An interactive, Shiny-based app for quality control of pharmacometrics datasets.利用 DataCheQC 提高药代动力学分析效率:一个基于 Shiny 的交互式应用程序,用于药代动力学数据集的质量控制。
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1375-1385. doi: 10.1002/psp4.13017. Epub 2023 Aug 18.
6
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).跨研究的药代动力学分析以推动知识整合:个体患者数据荟萃分析(IPDMA)教程。
CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1187-1200. doi: 10.1002/psp4.13002. Epub 2023 Jun 11.
7
Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses.艾沙康唑在新冠病毒相关肺曲霉病重症监护患者中的群体药代动力学及高超说明书剂量的蒙特卡洛模拟
J Fungi (Basel). 2023 Feb 6;9(2):211. doi: 10.3390/jof9020211.
8
Pharmacometric model of agalsidase-migalastat interaction in human: a novel mechanistic model of drug-drug interaction between a therapeutic protein and a small molecule.人源阿加糖酶-米加司他相互作用的药代动力学模型:一种治疗性蛋白质与小分子之间药物-药物相互作用的新型机制模型。
J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):63-74. doi: 10.1007/s10928-022-09830-y. Epub 2022 Nov 14.
9
Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout.健康受试者和痛风患者非布司他的群体药代动力学模型研究。
Br J Clin Pharmacol. 2022 Dec;88(12):5359-5368. doi: 10.1111/bcp.15462. Epub 2022 Jul 28.
10
Design and conduct considerations for studies in patients with impaired renal function.肾功能损害患者研究的设计和实施考虑因素。
Clin Transl Sci. 2021 Sep;14(5):1689-1704. doi: 10.1111/cts.13061. Epub 2021 Jun 25.

本文引用的文献

1
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.Piraña 和 PCluster:NONMEM 的建模环境和集群基础设施。
Comput Methods Programs Biomed. 2011 Jan;101(1):72-9. doi: 10.1016/j.cmpb.2010.04.018. Epub 2010 Jun 2.
2
Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.克林沙星在健康志愿者和感染患者中的群体药代动力学:异质性药代动力学数据的经验
Clin Pharmacokinet. 2001;40(4):307-15. doi: 10.2165/00003088-200140040-00006.
3
Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.儿童辅助拉莫三嗪治疗群体药代动力学模型的验证
Br J Clin Pharmacol. 2000 Aug;50(2):135-45. doi: 10.1046/j.1365-2125.2000.00237.x.
4
A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.多西他赛(泰索帝)的群体药代动力学模型:模型构建与验证
J Pharmacokinet Biopharm. 1996 Apr;24(2):153-72. doi: 10.1007/BF02353487.
5
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH).人用药品注册技术要求国际协调会议(ICH)
Br J Clin Pharmacol. 1994 May;37(5):401-4. doi: 10.1111/j.1365-2125.1994.tb05705.x.
6
Validation of simple and complex models in physiology and medicine.
Am J Physiol. 1984 Feb;246(2 Pt 2):R259-66. doi: 10.1152/ajpregu.1984.246.2.R259.

群体药代动力学-药效学分析质量控制指南:行业视角。

Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective.

机构信息

Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL 60062, USA.

出版信息

AAPS J. 2012 Dec;14(4):749-58. doi: 10.1208/s12248-012-9387-9. Epub 2012 Jul 24.

DOI:10.1208/s12248-012-9387-9
PMID:22826033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3475847/
Abstract

Quality population modeling and simulation analyses and reports are something every modeler desires. However, little attention in the literature has been paid to what constitutes quality regarding population analyses. Very rarely do published manuscripts contain any statement about quality assurance of the modeling results contained therein. The purpose of this manuscript is to present guidelines for the quality assurance of population analyses, particularly with regards to the use of NONMEM from an industrial perspective. Quality guidelines are developed for the NONMEM installation itself, NONMEM data sets, control streams, output listings, output data files and resultant post-processing, reporting of results, and the review processes. These guidelines were developed to be thorough yet practical, though are not meant to be completely comprehensive. It is our desire to ensure that what is reported accurately reflects the collected data, the modeling process, and model outputs for a modeling project.

摘要

质量人群建模和模拟分析及报告是每位建模师都渴望的。然而,文献中几乎没有关注什么是人群分析的质量。很少有发表的手稿包含任何关于建模结果质量保证的声明。本文的目的是提出人群分析质量保证的指南,特别是从工业角度使用 NONMEM。质量指南是针对 NONMEM 安装本身、NONMEM 数据集、控制流、输出列表、输出数据文件以及随后的后处理、结果报告和审查过程开发的。这些指南旨在全面而又实用,虽然并不意味着完全全面。我们希望确保报告准确反映建模项目的收集数据、建模过程和模型输出。